A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528 · Completed

Last updated 2026-05-28

This study tests a once-daily injection called NNC0090-2746 in adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 108 people

Who can join all sexes

Timeline Started 2014-08 · est. completion 2015-09

Where 20 sites · United States

What this study is testing ClinicalTrials.gov NCT02205528 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.

Treatments tested

Liraglutide Drug

Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
Metformin Drug

Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Placebo Drug

Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
NNC0090-2746 Drug

NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02205528 ↗